Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q2 2021 · 10-Q
Revenue$287.60K$287.60K+154.7% vs Q2 2020 Net Income-$1.11M-$1.11MN/M vs Q2 2020 EPS Diluted-$0.13-$0.13N/M vs Q2 2020 Operating Income-$1,127,651N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-392.1%+477.9 pt vs Q2 2020
Net margin-384.8%+459.7 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end